In the “ACC/AHA Guidelines for the Management of Patients With Unstable Angina and Non–ST-Segment Elevation Myocardial Infarction: Executive Summary and Recommendations” by Braunwald et al that appeared in a previous issue of the journal (Circulation. 2000;102:1193–1209), the following errors need to be corrected.
On Page 1195 in Table 1⇓ in the “Low Risk” column, the first entry should read: “New-onset or progressive CCS Class III or IV angina in the past 2 weeks without prolonged (>20 min) rest pain but with moderate or high likelihood of CAD.”
In the same Table⇓ under the “High Risk” column. “Cardiac markers” row, in the first line of the entry, delete “markedly” to read: “Elevated (eg, TnT or TnI >0.1 ng/mL).
The correct table follows.
On page 1201 in the first column under Recommendation 4, 4th line, “(see Table 2)” should be replaced with “(see Table 1⇓).” The recommendation should read:
4. A platelet GP IIb/IIIa receptor antagonist should be administered, in addition to ASA and UFH, to patients with continuing ischemia or with other high-risk features (see Table 1⇓) and to patients in whom a percutaneous coronary intervention (PCI) is planned. Eptifibatide and tirofiban are approved for this use. (Level of Evidence: A) Abciximab can also be used for 12 to 24 hours in patients with UA/NSTEMI in whom a PCI is planned within the next 24 hours. (Level of Evidence: A)
On page 1203 in Figure 4⇓ in “All” graph on the left, “3.9%” should be changed to “2.9%.” The corrected figure follows.
On page 1206 under “Recommendations for Postdischarge Therapy,” change >125 mg/dL to >130 mg/dL in item 10. The recommendation should read:
10. Lipid-lowering agents and diet in post ACS patients including patients who are post revascularization with low-density lipoprotein (LDL) cholesterol of >130 mg/dL, including after revascularization. (Level of Evidence: A)
- Copyright © 2001 by American Heart Association